THE POSSIBILITIES OF USING HUMIC ACIDS IN THE TREATMENT OF DISEASES OF THE GENITOURINARY SYSTEM



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the last decade, the problem of diseases of the genitourinary system has attracted more and more attention, due to their high percentage in the structure of general morbidity and mortality of the population. In this regard, the relevance of the search and development of new medicines for the treatment of this group of diseases is increasing. Of particular interest are preparations based on natural compounds of their derivatives, which are characterized by high biological activity and a favorable safety profile. One of the most interesting and poorly studied classes of biologically active natural compounds are humic acids. The purpose of this review is to summarize and systematize the information currently available on the known pharmacological effects and possible mechanisms of action of humic acids, as well as the prospects for their use in the treatment and prevention of diseases of the genitourinary system.

Full Text

Restricted Access

About the authors

Nikita S. Benderskii

Rostov State Medical University

Author for correspondence.
Email: cornance@yandex.ru
ORCID iD: 0000-0002-7636-1684
SPIN-code: 5966-0480

resident physician

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Leila A. Balurova

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0000-9265-3380

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Naila R. Yusupova

Rostov State Medical University

Email: cornance@yandex.ru

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Daria V. Berezovskaya

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0005-1813-0895

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Elizaveta E. Popova

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0001-0315-7199

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Grigory G. Yakovlev

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0002-7748-2696

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Maxim V. Gaivorontsev

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0007-9072-2005

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Yana V. Khodosenko

Rostov State Medical University

Email: cornance@yandex.ru
ORCID iD: 0009-0003-4502-9851

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

Inna E. Dzhemoldinova

Rostov State Medical University

Email: cornance@yandex.ru

student

Russian Federation, 29, Nakhichevansky Lane, Rostov-on-Don, 344022, Russia

References

  1. Dirks J., Remuzzi G., Horton S., et al. Diseases of the Kidney and the Urinary System. Jamison D.T., Breman J.G., Measham A.R., et al., editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington: The International Bank for Reconstruction and Development; 2006.
  2. Stamm W. E., Norrby S. R. Urinary tract infections: disease panorama and challenges. The Journal of infectious diseases. 2001; 183(1): S1-S4.
  3. Bergeron-Boucher M. P., Aburto J. M., van Raalte A. Diversification in causes of death in low-mortality countries: emerging patterns and implications. BMJ global health. 2020; 5(7): e002414.
  4. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization. 2004. 146 p.
  5. Zhu C., Wang D.Q., Zi H., et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Military Medical Research. 2021; (8): 1-12.
  6. Zi H., He S. H., Leng X. Y., et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019. Military Medical Research. 2021; 8(1): 1-15.
  7. Luyckx V. A., Tonelli M., Stanifer J. W. The global burden of kidney disease and the sustainable development goals. Bulletin of the World Health Organization. 2018; 96(6): 414.
  8. Kim M. M., Harvey J., Gusev A., et al. A scoping review of the economic burden of non-cancerous genitourinary conditions. Urology. 2022; (166): 29-38.
  9. Litwin M.S, Saigal C.S, editors. Urologic Diseases in America. Washington: US Government Printing Office; 2012.
  10. Orlov D. S. Guminovye veshchestva v biosphere. Sorosovskij obrazovatel'nyj zhurnal 1997; (2): 56-63. (In Russ).
  11. Perminova I.V. Analiz, klassifikaciya i prognoz svojstv gumusovyh kislot [dissertation]. Moscow; 2000. Available from: http://mgumus.chem.msu.ru/publication/01-titul.pdf. (In Russ).
  12. Avvakumova N.P. Sostav i biologicheskie svojstva gumusovyh kislot peloidov: fundamental'nye i prikladnye aspekty [dissertation]. Samara; 2003. Available from: http://dlib.rsl.ru/rsl01002000000/rsl01002606000/rsl01002606904/rsl01002606904.pdf. (In Russ).
  13. Danchenko N.N. Funkcional'nyj sostav gumusovyh kislot: Opredelenie i vzaimosvyaz' s reakcionnoj sposobnost'yu [dissertation]. Moscow; 1997. Available from: http://www.mgumus.chem.msu.ru/researches/Avtoreferaty/danchenko-diss.pdf. (In Russ).
  14. Aleksandrova, L.N. Organicheskoe veshchestvo pochvy i processy ee transformacii. Leningrad: Nauka. Leningradskoe otdelenie, 1980. (In Russ).
  15. Kononova M.M. Problema pochvennogo gumusa i sovremennye zadachi ego izucheniya. Moskva: Izdatel'stvo Akademii nauk SSSR, 1951. (In Russ).
  16. Lishtvan I.I., Kruglickij N.N., Tretinnik V.U. Fiziko-himicheskaya mekhanika guminovyh veshchestv. Minsk: Nauka i tekhnika, 1976. (In Russ).
  17. Orlov D.S. Gumusovye kisloty pochv i obshchaya teoriya gumifikacii. M. : Izdatel'stvo MGU, 1990. (In Russ).
  18. ZHdanova A.V. Izuchenie strukturnyh komponentov i fiziko-himicheskih svojstv guminovyh veshchestv nizkomineralizovannyh ilovyh sul'fidnyh gryazej kak istochnika antioksidantnyh lekarstvennyh sredstv [dissertation]. Samara; 2011. Available from: http://dlib.rsl.ru/rsl01004000000/rsl01004846000/rsl01004846945/rsl01004846945.pdf. (In Russ).
  19. Avvakumova N.P., Glubokova M.N., ZHdanova A.V., et al. Optimizaciya dializa guminovyh kislot. Izvestiya Samarskogo nauchnogo centra RAN. 2009; 1(6): 1256-1258. (In Russ).
  20. Murbach T. S., Glávits R., Endres J. R., et al. A toxicological evaluation of a fulvic and humic acids preparation. Toxicology reports. 2020; (7): 1242-1254.
  21. Gandy J. J., Meeding J. P., Snyman J. R., et al. Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid. Clinical Pharmacology: Advances and Applications. 2012; 4(7): 7-11.
  22. Gnananath K., Nataraj K. S., Rao B. G., et al. Exploration of fulvic acid as a functional excipient in line with the regulatory requirement. Environmental Research. 2020; (187): 109642.
  23. Dai C., Xiao X., Yuan Y., et al. A comprehensive toxicological assessment of fulvic acid. Evidence-Based Complementary and Alternative Medicine. 2020; (2020): 2020.
  24. Flores-Mireles A. L., Walker J. N., Caparon M., et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature reviews microbiology. 2015; 13(5): 269-284.
  25. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. The American journal of medicine. 2002; 113(1): 14-19.
  26. Paul R. State of the globe: Rising antimicrobial resistance of pathogens in urinary tract infection. Journal of Global Infectious Diseases. 2018; 10(3): 117.
  27. Li X., Fan H., Zi H., et al. Global and regional burden of bacterial antimicrobial resistance in urinary tract infections in 2019. Journal of Clinical Medicine. 2022; 11(10): 2817.
  28. Tadigieva N.Z., Coj E.G., Turovskaya S.I. Antibakterial'naya aktivnost' guminovogo preparata iz lechebnoj torfyanoj gryazi Dzhelal. Biologicheskie nauki. 1991; (10): 109-113.
  29. Krasnikova E.S., Pavlenko V.V., Matrenov I.S. Izuchenie baktericidnoj i fungicidnoj aktivnosti kormovoj dobavki na osnove guminovyh kislot. Uchenye zapiski Kazanskoj gosudarstvennoj akademii veterinarnoj mediciny im. N.E Baumana. 2019; 239(3): 158-160. (In Russ).
  30. Verrillo M., Salzano M., Meo V. D., et al. Antibacterial and antioxidant properties of humic substances from composted agricultural biomasses. Chemical and Biological Technologies in Agriculture. 2022; 9(1): 28.
  31. Hassett D.J., Bisesi M.S., Hartenstein R. Bactericidal action of humic acids. Soil Biology and Biochemistry. 1987; 19(1): 111-113.
  32. Khuda F., Anjum M., Khan S., et al. Antimicrobial, anti-inflammatory and antioxidant activities of natural organic matter extracted from cretaceous shales in district Nowshera-Pakistan. Arabian Journal of Chemistry. 2022; 15(2): 103633.
  33. Litvin V.A., Njoh R.A. Quercetin as a precursor in the synthesis of analogues of fulvic acids and their antibacterial properties. Voprosy khimii i khimicheskoi tekhnologii. 2021; (2): 56-64.
  34. Ansorg R., Rochus W. Studies on the antimicrobial effect of natural and synthetic humic acids. Arzneimittel-forschung. 1978; 28(12): 2195-2198.
  35. Leivers S.W., Warn P., inventor; Natracine UK Limited, assignee. Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria. United States patent US 9265744B2. 2016 Feb 23.
  36. Zhao Y., Paderu P., Delmas G., et al. Carbohydrate-derived fulvic acid is a highly promising topical agent to enhance healing of wounds infected with drug-resistant pathogens. Journal of Trauma and Acute Care Surgery. 2015; 79(4): S121-S129.
  37. Gorovaya A.I., Orlov D.S., SHCHerbenko O.V. Guminovye veshchestva. Kiev: Naukova dumka, 1995. (In Russ).
  38. Popov A.I., Zelenkov V.N., Teplyakova T.V. Biologicheskaya aktivnost' i biohimiya guminovyh veshchestv. CHast' 2. Mediko-biologicheskij aspekt. (Obzor literatury) // Vestnik Rossijskoj Akademii estestvennyh nauk. 2016; (5): 9-16. (In Russ).
  39. Man D., Pisarek I., Braczkowski M., et al. The impact of humic and fulvic acids on the dynamic properties of liposome membranes: the ESR method. Journal of Liposome Research. 2014; 24(2): 106-112.
  40. de Wit H. Proton and metal ion binding to humic substances. Wageningen: Wageningen University and Research, 1992.
  41. de Melo B.A.G., Motta F.L., Santana M.H.A. Humic acids: Structural properties and multiple functionalities for novel technological developments. Materials Science and Engineering. 2016; (62): 967-974.
  42. Mikhnevich T.A., Vyatkina A.V., Grigorenko V.G., et al. Inhibition of class A β-lactamase (TEM-1) by narrow fractions of humic substances. ACS omega. 2021; 6(37): 23873-23883.
  43. Kravtsova D., Cherkasova T., Rubtsova M., et al. Humic substances potentiate inhibitory activity of sulbactam with respect to β-lactamase TEM-1. // Perminova I., editors. Fifth International Conference of CIS IHSS on Humic Innovative Technologies «Humic substances and living systems» (HIT-2019); 2019 October 19–23; Moscow, Russia. Moscow: Desktop publishing by Alexander Polyakov; 2019. p. 105.
  44. Fernandes A.C., Medlen C.E., Leivers S., inventor; Pfeinsmith Ltd., assignee. Fulvic acid and antibiotic combination. United States patent US 8445452B2. 2013 May 21.
  45. Dias V. Candida species in the urinary tract: is it a fungal infection or not?. Future microbiology. 2020; 15(2): 81-83.
  46. Sobel J. D., Fisher J. F., Kauffman C. A., et al. Candida urinary tract infections-epidemiology. Clinical Infectious Diseases. 2011; 52(6): 433-436.
  47. Carvalho M., Guimarães C. M., Mayer Júnior J. R., et al. Hospital-associated funguria: analysis of risk factors, clinical presentation and outcome. Brazilian Journal of Infectious Diseases. 2001; (5): 313-318.
  48. Sobel J.D., Vazquez J.A. Fungal infections of the urinary tract. World J Urol. 1999; (17): 410–14.
  49. Rafal'skij V.V. Klinicheskoe znachenie i terapiya kandidurii // Klinicheskaya mikrobiologiya i antimikrobnaya himioterapiya. 2001; 3(1): С. 22–27. (In Russ).
  50. Beloborodov V.B., Sinyakova L.A. Nozokomial'naya kandiduriya: algoritm diagnostiki i lecheniya. Consilium medicum. 2003; 5(7): 380–84. (In Russ).
  51. Rex J.H., Walsh T.J., Sobel J.D., et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000; (30): 662–78.
  52. Kauffman, C.A. Diagnosis and management of fungal urinary tract infection. Infect. Dis. Clin. N. Am. 2014; (28): 61–74.
  53. Achkar, J.M.; Fries, B.C. Candida infections of the genitourinary tract. Clin. Microbiol. Rev. 2010; (23): 253–273.
  54. Sherry L., Murray C., Ramage G. Carbohydrate Derived Fulvic Acid (CHD-FA) is a Novel Antifungal Product: Category: Scientific free paper. Journal of Infection. 2011; 63(6): e99.
  55. Dekker J., Medlen C.E., inventor; Enerkom (Proprietary) Limited, assignee. Fulvic acid and its use in the treatment of candida infections. United States patent US 6569900B1. 2003 May 27
  56. Nivetha M., Sujatha S. Phytochemical analysis, antibacterial, antifungal and antiinflammatory activity of humic acid. International Journal of Research and Analytical Reviews. 2019; 6(1): 853-858
  57. Sherry L., Jose A., Murray C., et al. Carbohydrate derived fulvic acid: an in vitro investigation of a novel membrane active antiseptic agent against Candida albicans biofilms. Frontiers in microbiology. 2012; (3): 116.
  58. Antoni S., Ferlay J., Soerjomataram I., et al. Bladder cancer incidence and mortality: a global overview and recent trends. European urology. 2017; 71(1): 96-108.
  59. Wang L., Lu B., He M., et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Frontiers in Public Health. 2022; (10): 811044.
  60. Sung H., Ferlay J., Siegel R. L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021; 71(3): 209-249.
  61. Şekerler T., Mısırlı D., Özsavcı D., et al. Paradoxical role of humic acid in some of cancer cell lines. Febs Journal. 2016; 283(1): 416.
  62. Jayasooriya R. G. P. T., Dilshara M. G., Kang C. H., et al. Fulvic acid promotes extracellular anti-cancer mediators from RAW 264.7 cells, causing to cancer cell death in vitro. International Immunopharmacology. 2016; (36): 241-248.
  63. Aydin S. K., Dalgic S., Karaman M., et al. Effects of fulvic acid on different cancer cell lines. Proceedings. 2017. 1(10): 1031.
  64. Kloskowski T., Szeliski K., Krzeszowiak K., et al. Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment. Scientific Reports. 2021; 11(1): 22614.
  65. Schepetkin I. A., Khlebnikov A. I., Ah S. Y., et al. Characterization and biological activities of humic substances from mumie. Journal of agricultural and food chemistry. 2003; 51(18): 5245-5254.
  66. Ashkenazi A., Dixit V. M. Death receptors: signaling and modulation. Science. 1998; 281(5381): 1305-1308.
  67. Brüne B. Nitric oxide: NO apoptosis or turning it ON?. Cell Death & Differentiation. 2003; 10(8): 864-869.
  68. Garbán H. J., Bonavida B. Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecologic oncology. 1999; 73(2): 257-264.
  69. Khan F. H., Dervan E., Bhattacharyya D. D., et al. The role of nitric oxide in cancer: master regulator or NOt?. International journal of molecular sciences. 2020; 21(24): 9393.
  70. Hseu Y. C., Huang H. W., Wang S. Y., et al. Humic acid induces apoptosis in human endothelial cells. Toxicology and applied Pharmacology. 2002; 182(1): 34-43.
  71. Salehi M., Piri H., Farasat A., et al. Activation of apoptosis and G0/G1 cell cycle arrest along with inhibition of melanogenesis by humic acid and fulvic acid: BAX/BCL-2 and Tyr genes expression and evaluation of nanomechanical properties in A375 human melanoma cell line. Iranian Journal of Basic Medical Sciences. 2022; 25(4): 489.
  72. Pant K., Gupta P., Damania P., et al. Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells. BMC complementary and alternative medicine. 2016; (16): 1-10.
  73. Dubishchev A. V., Zajceva E. N., Makarenko N. V. Mekhanizm dejstviya guminovyh kislot na vydelitel'nuyu funkciyu pochek v norme i pri gentamicinovoj nefropatii. Ukraїns'kij bіofarmacevtichnij zhurnal. 2014; (5): 13-15. (In Russ).
  74. Slobodyan E. I., Kaladze N. N., Govdalyuk A. L., et al. Nefroprotektivnyj potencial peloidoterapii v reabilitacii bol'nyh hronicheskim pielonefritom. Voprosy kurortologii, fizioterapii i lechebnoj fizicheskoj kul'tury. 2017; 94(3): 62-68. (In Russ).
  75. Men'shih L. E., Dubishchev A. V. Guminovye kisloty kak faktor zashchity ot nefrotoksicheskogo dejstviya gentamicina. Izvestiya Samarskogo nauchnogo centra Rossijskoj akademii nauk. 2011; 13(8): 2021-2025. (In Russ).
  76. Dubishchev A. V., Men'shih L. E. Issledovanie vliyaniya guminovyh veshchestv peloidov na ekskretornuyu funkciyu pochek. Izvestiya Samarskogo nauchnogo centra Rossijskoj akademii nauk. 2010; 12(8): 2023-2026. (In Russ).
  77. Makarenko N. V., Zajceva E. N., Dubishchev A. V., et al. Issledovanie ostroj toksichnosti i diureticheskoj aktivnosti metalloproizvodnyh guminovyh, ful'vovyh i gumusovyh kislot. Izvestiya Samarskogo nauchnogo centra Rossijskoj akademii nauk. 2015; 17(3): 925-929. (In Russ).
  78. Makarenko N. V., Zajceva E. N., Dubishchev A. V. Analiz vliyaniya ful'vatov magniya, kal'ciya i marganca na ekskretornuyu funkciyu pochek. Izvestiya Samarskogo nauchnogo centra Rossijskoj akademii nauk. 2015; 17(2): 273-278. (In Russ).
  79. Akbas A., Silan C., Gulpinar M. T., et al. Renoprotective effect of humic acid on renal ischemia-reperfusion injury: An experimental study in rats. Inflammation. 2015; (38): 2042-2048

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия  ПИ № ФС 77 - 86296 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies